The validated CellSearch system (Menarini Silicon BioSystems), utilizing an immunomagnetic CTC selection method based on an rare cell capture technology (RCCT) and anti-epithelial cell adhesion molecule (EPCAM) antibody-conjugated ferroparticles, is an FDA-approved methodology for enumerating CTC from blood in patients with breast, prostate and colon cancers (27–31). This evidence concerns the gene EPCAM and malignant colon neoplasm.